Table 5 Rituximab vs. cyclophosphamide in the treatment of SLE or AAV
| Â | Pediatric rheumatologists | Pediatric nephrologists | p-value |
|---|---|---|---|
n = 56 (100%) | n = 31 (100%) | ||
Would you use CYC and RTX together for induction therapy? | Â | ||
 Yes | 13 (23%) | 5 (16%) | 0.360 |
What drives you to choose CYC or RTX for SLE or AAV? | |||
 Clinical experience | 36 (64%) | 18 (58%) | 0.566 |
 Efficacy | 37 (66%) | 16 (52%) | 0.185 |
 Ease of use of the treatment | 11 (20%) | 8 (26%) | 0.505 |
 Side effect profile | 32 (57%) | 15 (48%) | 0.432 |
 Availability | 27 (48%) | 22 (71%) | 0.040 |
 Patient’s age | 24 (43%) | 14 (45%) | 0.835 |
 Cost | 17 (30%) | 9 (29%) | 0.897 |
 Patient/caregiver choice | 17 (30%) | 6 (19%) | 0.265 |
 Disease severity | 6 (11%) | 6 (19%) | 0.263 |